A detailed history of Capital Performance Advisors LLP transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 3 shares of YMAB stock, worth $33. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3
Holding current value
$33
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$9.95 - $15.39 $29 - $46
3 New
3 $0

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.